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West Nile virus (WNV) is a neurotropic flavivirus within the Japanese encephalitis antigenic complex that is responsible for causing West Nile
encephalitis in humans. The surface of WNV virions is covered by a highly ordered icosahedral array of envelope proteins that is responsible for
mediating attachment and fusion with target cells. These envelope proteins are also primary targets for the generation of neutralizing antibodies in
vivo. In this study, we describe a novel approach for measuring antibody-mediated neutralization of WNV infection using virus-like particles that
measure infection as a function of reporter gene expression. These reporter virus particles (RVPs) are produced by complementation of a sub-
genomic replicon with WNV structural proteins provided in trans using conventional DNA expression vectors. The precision and accuracy of this
approach stem from an ability to measure the outcome of the interaction between antibody and viral antigens under conditions that satisfy the
assumptions of the law of mass action as applied to virus neutralization. In addition to its quantitative strengths, this approach allows the
production of WNV RVPs bearing the prM-E proteins of different WNV strains and mutants, offering considerable flexibility for the study of the
humoral immune response to WNV in vitro. WNV RVPs are capable of only a single round of infection, can be used under BSL-2 conditions, and
offer a rapid and quantitative approach for detecting virus entry and its inhibition by neutralizing antibody.
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West Nile virus (WNV) is a neurotropic flavivirus that is the
etiologic agent responsible for West Nile encephalitis in
humans (reviewed in Brinton, 2002). Despite being endemic
in many parts of Africa, Europe, Asia, and the Middle East,
WNV was not introduced into the western hemisphere until the
late summer of 1999 (Lanciotti et al., 1999; Marfin and Gubler,0042-6822/$ - see front matter. Published by Elsevier Inc.
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doms@mail.med.upenn.edu (R.W. Doms).2001). During subsequent years, WNV spread across much of
North America and can now be found in a variety of avian,
mosquito, and mammalian species throughout the United
States, Canada, and Mexico (Granwehr et al., 2004). The rapid
spread of WNV across North America during the past 5 years
identifies this virus as an important emerging pathogen for the
western hemisphere.
In nature, WNV exists in an enzootic cycle between birds
and mosquitoes, although several incidental vertebrate species
can be infected including humans (Marfin and Gubler, 2001).
While the majority of individuals exposed to WNV remain
asymptomatic, a spectrum of disease has been reported that
ranges from a mild febrile illness to severe meningoencepha-
litis (Petersen et al., 2003). However, only a small fraction of
individuals experience these more serious clinical complica-
tions of infection. The age and the immune status of the06) 53 – 65
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severity of WNV associated disease (Chowers et al., 2001;
Nash et al., 2001; Tsai et al., 1998). While no specific therapy
for WNV infection currently exists, the development of
immunotherapeutics (Oliphant et al., 2005) and vaccines
(Despres et al., 2005; Karaca et al., 2005; Lustig et al., 2000;
Siger et al., 2004; Tesh et al., 2002; Turell et al., 2003) is an
active area of investigation.
Structural and cryo-electron microscopy studies reveal that
the surface of the flavivirus virion is composed of a highly
ordered icosahedron of 180 envelope (E) proteins (Ferlenghi et
al., 2001; Kuhn et al., 2002; Modis et al., 2003, 2005;
Mukhopadhyay et al., 2003, 2005; Rey et al., 1995). The
generation of antibodies capable of binding to this array of viral
proteins and blocking infection is an important aspect of the
immune response and a goal of vaccine development. Passive
immunization studies and experimental infections of immuno-
deficient mice demonstrate that antibody plays a significant
role in protection from and clearance of WNV (reviewed in
Diamond et al., 2003). The importance of antibodies in vivo
reflects their ability to directly neutralize virus infectivity
(Oliphant et al., 2005), facilitate complement-mediated lysis of
virions (Mehlhop et al., 2005) and promote efficient viral
clearance through Fc-dependent pathways (Oliphant et al.,
2005). Characterizing the humoral immune response to WNV
infection or vaccination will facilitate the development of safe
and effective vaccination and immunotherapeutic strategies.
The majority of existing approaches for the study of
WNV neutralization measure the inhibition of virus entry as
a reduction in the number of plaques formed on monolayers
of suitable cell lines (Lindsey et al., 1976; Morens et al.,
1985; Russell and Nisalak, 1967; Russell et al., 1967).
While a great deal has been learned about WNV and other
flaviviruses using these methods, they have limitations
including a requirement for an appropriate biocontainment
facility and a reliance on viral strains and cell types for
which plaque formation can be readily visualized and
enumerated. To complement and extend these approaches,
we describe a novel approach for measuring antibody-
mediated neutralization of WNV infection using virus-like
particles (reporter virus particles: RVPs) that encapsidate a
sub-genomic replicon capable of expressing a reporter gene
following infection of target cells. Production of RVPs is
accomplished by complementation of replicon RNA with
WNV structural genes expressed in trans (Jones et al.,
2005; Khromykh et al., 1998; Scholle et al., 2004). The
resulting particles can be used to study the outcome of the
interaction between antibody and viral antigens under
conditions that satisfy the assumptions of the law of mass
action as applied to virus neutralization, increasing accuracy
and reproducibility (Klasse and Sattentau, 2001). In addition
to the quantitative power of the approach, an ability to
produce RVPs incorporating the structural proteins of a
large number of WNV strains and variants confers a
considerable degree of flexibility. In this study, we
demonstrate that WNV RVPs offer a rapid and quantitative
approach for measuring virus entry in vitro and itsinhibition that is amenable to analysis of neutralization on
many different cell types.
Results
Production of WNV reporter virus particles (RVPs)
We have developed methods for the production of pseudo-
infectious WNV reporter virus particles (RVPs) that allow a
rapid and quantitative measure of WNV infection and its
inhibition by neutralizing antibodies. The accuracy of this
approach relies on the ability to measure the outcome of
virion–antibody interactions using conditions that satisfy the
assumptions of the law of mass action as applied to virus
neutralization (reviewed in Klasse and Sattentau, 2001). RVPs
are composed of a sub-genomic WNV replicon that is
packaged into an enveloped virus particle by the capsid and
envelope proteins of the virus when provided in trans (Jones et
al., 2005; Khromykh et al., 1998; Scholle et al., 2004). Using
the work of Khromykh and colleagues as a model, we
constructed a panel of replicons that express one or more
reporter genes by modifying a molecular clone of a lineage II
strain of WNV (Fig. 1) (Khromykh and Westaway, 1997)
(reviewed in Khromykh, 2000). Each replicon was designed to
facilitate the introduction of reporter genes in place of the
structural genes (via a novel MluI site) or in the 3V UTR under
the translational control of an internal ribosome entry site
(IRES) (via a novel NotI site). In addition, these vectors were
engineered to place the sub-genomic WNV RNA under the
transcriptional control of the CMV immediate early promoter/
enhancer. This ‘‘DNA-launched’’ format allows the introduc-
tion of replicon RNA into cells using standard transfection
methodologies (Pierson et al., 2005; Varnavski et al., 2000),
eliminating the requirement to produce and purify the
approximately 11 kb, 7mG-capped RNA that is associated
with many flavivirus replicons and molecular clones.
Production of WNV RVPs was accomplished by transfec-
tion of HEK-293T cells with three plasmids that encode capsid,
the envelope proteins (pre-membrane (prM) and E), and a
replicon (WNIIrep-GFP). Two days after transfection, RVP-
containing supernatants were harvested, filtered, and used to
infect target cells. RVP-infected BHK-21 cells were analyzed
at 36 h post-infection for the expression of GFP by flow
cytometry (Fig. 2). Using this approach, we found that
infectious RVPs capable of transducing target cells were
released at a titer of approximately 1.0  106 infectious
particles per milliliter, as measured by GFP expression in
BHK-21 cells. As expected, the production of infectious
particles required expression of all three components in the
producer cell (Fig. 2). To simplify this RVP production
approach, without imposing limitations on the nature of
structural proteins incorporated into the virus particle, we
created BHK-21 cell lines that stably propagate bicistronic
WNV replicons. BHK-21 cells that propagate replicons were
produced by infection with RVPs that encapsidated a
bicistronic replicon encoding both a reporter gene and the
gene conferring resistance to blasticidin, followed by selection
Fig. 1. Schematic of a sub-genomic WNV replicon. A panel of sub-genomic replicons of a lineage II strain of WNV was constructed by sequential modification of an
existing molecular clone of the virus. Most of the sequence encoding the structural genes were removed and replaced with sequence encoding the autoprotease of
FMDVand a unique MluI restriction endonuclease recognition site. A second unique restriction site (NotI) was cloned into the 3VUTR. Both sites were used for the
introduction of a variety of reporter genes, although genes inserted into the NotI sites could only be expressed under the translational control of an IRES. In addition,
the replicon RNAwas engineered under the transcriptional control of the constitutive promoter/enhancer of CMV. A critical aspect of this design was to position the
5V terminal nucleotides of the replicon at the transcription start site of the promoter and introduce a ribozyme at the 3V end of the genome to generate the specific 3V
terminus of the replicon RNA.
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generated that expressed either WNV replicons encoding
GFP (BHK WNIIrep-GFP) or Renilla luciferase (BHK
WNIIrep-REN). In subsequent experiments, we found that
the WNV RNAs replicating in each of these stable cell lines
were capable of being packaged into infectious RVPs when
cells were transfected with vectors encoding the structural
proteins. However, similar titers were obtained as compared to
approaches in which the replicon was transfected along with
the plasmids encoding structural proteins, indicating that these
cell lines simplify but do not enhance RVP production (data
not shown).Fig. 2. Production of WNV RVPs by complementation. HEK-293T cells were
plated in 24-well plates and transfected in triplicate with an equal mass of the
indicated plasmids (4 Ag total) (x-axis), where rep indicates a GFP-expressing
WNV replicon (WNIIrep-GFP). RVPs were harvested at 48 h from each well
and used to infect pre-plated BHK-21 cells in duplicate. The data presented are
the average infection of RVPs from each triplicate transfection. Two days after
infection, cells were harvested, and the percentage of cells expressing GFP was
determined by flow cytometry.Neutralization of WNV RVPs
To evaluate the utility of RVPs for the study of antibody-
mediated neutralization, we performed a series of experiments
to confirm that neutralization of RVP infection could be
measured as a function of reporter gene expression. These
studies were performed using monoclonal antibody (mAb)
7H2, which blocks WNV infection through high affinity
interactions with a neutralizing epitope on the upper lateral
surface of the domain III region of the E protein (Beasley and
Barrett, 2002; Oliphant et al., 2005; Sanchez et al., 2005; Volk
et al., 2004). WNV RVPs were produced in WNIIrep-GFP
transfected HEK-293T cells and incubated in the presence of a
high concentration of mAb 7H2 prior to infection of BHK-21
cells. Incubation with mAb 7H2 blocked greater than 90% of
WNV RVP infection, whereas an irrelevant control antibody
had no inhibitory effect (Fig. 3A). Analysis of the level of GFP
expression in cells infected with RVP in the presence of sub-
neutralizing quantities of mAb confirmed that the presence of
neutralizing antibody resulted in a reduction in the number of
cells infected by RVPs, rather than an overall reduction in
reporter gene activity in each infected cell (Fig. 3B). Although
it is intuitive for experiments in which neutralization can be
measured directly as a reduction in the percentage of infected
cells, this control provides support for high throughput
approaches in which infection is measured by catalysis of
luminescent or fluorescent substrates.
Development of an assay to provide a quantitative and
accurate measure of the neutralizing potency of an antibody
or sera is dependent upon use of appropriate normalization
conditions and validation parameters. The ‘‘percentage law’’
states that the proportion of virus neutralized by any given
concentration of antibody will remain constant even when
the concentration of the virus input is varied (Andrewes and
Fig. 4. Impact of RVP concentration on neutralization potency of 7H2. WNV
RVPs were produced in HEK-293T cells transfected with an equal mass o
WNIIrep-GFP, WNV capsid, and WNV prM-E proteins using Lipofectamine
2000. WNV RVPs were harvested at 48 h post-transfection and diluted as
indicated prior to addition of antibody. Antibodies were incubated with RVPs a
the indicated concentrations for 1 h at room temperature in complete media
Pre-plated BHK-21 cells were infected in 48-well plates in a total volume o
200 Al. Infection was analyzed at 36 h post-infection by flow cytometry. Non
linear regression analysis to predict the EC50 of mAb 7H2 at each concentration
of RVPs was performed using Graph Pad Prism, revealing an EC50 of 170, 32
and 11 ng/ml 7H2 for RVPs diluted 0-, 4-, or 16-fold prior to analysis. Dotted
lines indicated the 95% confidence interval for the regression analysis and erro
bars reflect the standard deviation at each point.
Fig. 3. Neutralization of WNV RVPs. WNV RVPs were produced in HEK-293T cells by transfection with plasmids encoding WNIIrep-GFP and the structural
proteins capsid and prM-E. (A) RVPs were harvested and incubated for 1 h in the presence or absence of 2.5 Ag/ml of either the mAb 7H2 or an irrelevant control
antibody specific for the C-type lectin DC-SIGN-R. Subsequently, RVPs were used to infect BHK-21 cells in a total volume of 250 Al. Antibody incubations and
infections were performed in triplicate. At 30 h post-infection, cells were harvested, and the percentage of cells expressing GFP was determined by flow cytometry.
Error bars reflect the standard deviation of the average value for each point. (B) Dot plot diagrams illustrating the intensity of replicon reporter gene expression in the
presence of varying concentrations of 7H2. Geometric mean channel fluorescence of cells in the GFP positive quadrant for no RVP, no 7H2, 2500 ng 7H2, and 80 ng
7H2 conditions was 0.0 (n = 0), 1183 (n = 2342), 785.8 (n = 5), and 1104 (n = 436), respectively (with the number of positive events indicated in parenthesis).
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2001 for review). The rationale behind this concept is based
on the observation that antibody-mediated neutralization of
virus infection typically obeys the law of mass action. In
the absence of cooperative effects:
The law of mass action predicts that the fraction of virus
particles neutralized by antibody ([mAbIV]/[V]) should
depend on the concentration of free antibody [mAb] and
the affinity of the antibody for viral antigen (Ka). During
neutralization experiments, the concentration of free mAb is
not measured directly but is assumed to be very close to the
total concentration of mAb added to the neutralization
reaction ([mAbTOT] = [mAb] + [mAbIV]). For this to occur,
antibody must be present in vast excess over the virus particles
at informative portions of the resulting neutralization curve,
such that as the reaction approaches equilibrium, the amount of
antibody in complex with virus particles will be a negligible
fraction of the amount of total antibody (reviewed in Klasse and
Sattentau, 2001, 2002). Conventional assays for measuring
antibody-mediated neutralization are standardized using a
defined number of infectious virus particles. Demonstrating
that this approach satisfies the assumptions of the percentage
law under all circumstances is cumbersome, particularly when
studying viruses (such as flaviviruses) that secrete significantamounts of soluble antigen or defective virus particles from
infected cells (Lobigs and Lee, 2004; Smith et al., 1970; Stollar,
1969), comparing different virus strains or preparations, or
studying antibodies that bind viral antigens with high affinity.f
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Fig. 5. Manipulating the amount of antigen present in WNV RVPs. (A)
Schematic of four different plasmid configurations used to express WNV
structural proteins during RVP production. (B) Infectivity of RVPs produced
using each transfection strategy was determined on BHK-21 cells. RVPs were
produced by transfection of BHK WNIIrep-REN cells with the indicated
plasmids using 1 Ag of plasmid expressing the E protein. Because different
numbers of plasmids were used in each production condition, in each case, a
total mass of 4 Ag plasmid was transfected, with empty pcDNA 3.1 plasmid
used to make up the difference in mass when required. RVPs were harvested
after 48 h and used to infect pre-plated BHK-21 cells in 96-well plates in
duplicate. Infection was monitored as a function of luciferase activity
(Promega). Similar studies were performed using Vero cells as target cells
and with RVPs encapsidating a GFP-expressing replicon. (C) To establish the
relationship between infectivity and the concentration of antigen present in
RVP preparations, samples were subjected to antigen capture ELISA. Data are
plotted as the concentration of E protein antigen (using a soluble monomeric
E protein standard) as a function of the Renilla luciferase activity (REN
activity).
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accordance with the percentage law, neutralization curves were
generated with varying concentrations of mAb 7H2 and WNV
RVPs. While RVP infection was reduced in a dose-dependent
fashion, the concentration of antibody required to block 50% of
theWNVRVP infection events was strongly dependent upon the
concentration of the virus (Fig. 4). In this regard, these initial
neutralization studies violated the percentage law because
relative to the affinity of mAb 7H2 for WNV antigen, the
amount of viral antigen present in each neutralization reaction
was too large. While this problem could be solved by a larger
dilution of RVPs prior to analysis, this would have the
undesirable effect of decreasing the signal to background ratio
and precision of the assay. Instead, we investigated the
possibility of reducing the amount of viral antigen present in
RVP preparations, without affecting the infectious titer.
Manipulating the level of non-infectious virus particles present
in WNV RVP preparations
An interesting aspect of flavivirus biology is the production
and release of small, non-infectious subviral particles (SVPs)
following expression of prM and E, which can occur in the
absence of expression of the viral RNA or any of the other
viral proteins (Allison et al., 1995, 2003; Schalich et al., 1996).
Importantly, SVPs are structurally and antigenically similar to
infectious virus particles and can be released from virus-
infected cells (Brinton, 1983; Ferlenghi et al., 2001; Lobigs
and Lee, 2004). Thus, factors that influence the relative
amount of SVPs present in virus preparations will alter the
amount of viral antigen associated with each infectious
particle. Studies of several different flavivirus systems suggest
that the incorporation of capsid into the virus particle is
controlled at least in part by the coordinated viral cleavage of
the capsid protein away from prM during translation of the
polyprotein at the ER (Lobigs and Lee, 2004). Therefore, we
sought to modify our complementation strategy to identify an
approach that yielded infectious RVPs with the smallest
amount of antigen.
Four different complementation strategies were investigat-
ed, using plasmids that expressed WNV structural genes in
different configurations (Fig. 5A). Surprisingly, all four
strategies produced infectious RVPs with a very similar titer
(Fig. 5B). In contrast, significant differences in the concentra-
tion of antigen were observed in supernatants containing RVPs.
RVPs produced using plasmids encoding a capsid-prM fusion
protein (C-prM-E and C-prM + E) yielded particles with the
lowest concentration of antigen per infectious unit (Fig. 5C),
consistent with the importance of cleavage of the capsid-prM
junction during formation of infectious virus particles (Lobigs
and Lee, 2004). In contrast, RVPs secreted from cells
transfected with plasmids encoding capsid and prM-E (C +
prM-E) were associated with relatively high concentrations of
E protein antigen. Thus, the particle to infectious particle ratio
in RVP preparations, as measured by the concentration of
antigen per infection event, can be manipulated using different
structural protein expression systems and production condi-tions. Moreover, complementation strategies that employ
capsid-prM and E protein expression vectors (C-prM + E)
are most favorable as they allow production of RVPs associated
with low concentrations of antigen and retain the additional
degree of safety afforded by the use of three separate genetic
elements.
Neutralization of RVPs in accordance with the percentage law
Having identified RVP production conditions that result in a
more favorable ratio of infectious particles to viral antigen, we
Fig. 6. Neutralization of WNV RVPs in accordance with the percentage law.
(A) WNV RVPs were produced in BHK WNIIrep-REN cells transfected with
plasmids encoding a WNV C-prM fusion protein and E protein (using a
plasmid ratio of 3:1 by mass) using Lipofectamine 2000. RVPs were diluted
as indicated and used in neutralization studies with the indicated concentra-
tions of mAb 7H2 in quadruplicate. At these dilutions, all preparations
contained less than 10 ng/ml E protein antigen. RVP–antibody complexes
were added to pre-plated BHK-21 cells in 96-well plates in 200 Al total
volume. Analysis of luciferase activity was performed at 40 h post-infection.
Non-linear regression analysis of the resulting data set was performed to
predict the EC50 of mAb 7H2 at each concentration of RVPs using Graph Pad
Prism. Dotted lines indicate the 95% confidence interval for the regression
analysis, and error bars reflect the standard deviation at each point. (B) The
neutralization activity of mAb 5H10 was determined using three independent,
antigen normalized preparations of WNV RVPs. In each case, RVPs were
produced in BHK WNIIrep-REN using the C-prM + E production approach
and frozen. The antigen concentration of RVPs was determined by ELISA
and adjusted to less than 10 ng/ml for each preparation prior to incubation
with mAb 5H10. Neutralization studies and analysis were performed as
described above.
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studies using an approach that satisfies the percentage law. We
established the concentration of E protein antigen as the sole
normalization parameter between experiments and virus
particle preparations and then sought to identify a concentra-
tion of viral antigen that was sufficiently low such that the
formation of RVP–antibody complexes would be negligible
relative to the concentration of antibody required to neutralize
half of the infectious particles (i.e., the EC50 of the mAb).
Because this parameter is strongly affected by the affinity of
the antibody studied, we employed high affinity antibodies for
analysis, providing the most stringent validation conditions
(Beasley and Barrett, 2002; Volk et al., 2004).
RVPs were produced in a BHK-21 cell line that stably
replicates a WNV replicon encoding Renilla luciferase (REN)
after transfection of plasmids expressing C-prM and E (C-
prM + E) (Fig. 5A). RVPs were harvested, analyzed for E
protein content by ELISA, aliquoted, diluted as indicated prior
to incubation with varying concentrations of mAb 7H2, and
then used to infect BHK-21 cells in a 96-well plate. Infection
and neutralization were monitored as a function of luciferase
activity at 40 h after infection. Non-linear regression analysis
predicted the EC50 of 7H2 at 6.5 ng/ml (95% confidence
interval (95%CI): 4.2–10 ng/ml), 3.8 ng/ml (95%CI: 2.5–5.9
ng/ml), and 6.6 ng/ml (95%CI: 3.7–11.6 ng/ml) for 10-, 20-,
and 40-fold dilutions of RVPs, respectively (Fig. 6A). Thus, in
contrast to data obtained with particles produced using the C +
prM-E approach, the potency of mAb 7H2 did not vary
significantly with increasing dilutions of particles. In addition,
increasing the volume of the neutralization reaction, while
maintaining the concentration of antibody, did not significantly
impact the neutralization titer of 7H2 (data not shown). Both
experiments directly test and validate compliance of these
assay conditions with the assumptions of the law of mass
action. Repeated analysis of the neutralization potency of mAb
7H2 (average EC50 of 6.8 ng/ml (T2.9 ng/ml (standard
deviation): n = 9)) or 5H10 (16.0 T 7.6 ng/ml: n = 10)
performed on more than five occasions using at least three
independent preparations of RVPs demonstrated a high degree
of accuracy and reproducibility (Fig. 6B). Interestingly, we
performed a smaller number of experiments using Vero cells
and found that the potency of each antibody was somewhat
greater than when BHK-21 cells were used as targets (5H10:
1.0 T 0.6 ng/ml (n = 8) and 7H2: 1.2 T 1.0 ng/ml (n = 5)),
consistent with previous work in other viral systems that
identify the impact of cellular factors on neutralization (Grady
and Kinch, 1985; Kjellen, 1985; Kjellen and von Zeipel, 1984;
Layne et al., 1991; Ruppach et al., 2000). This RVP system
will make it possible to more readily identify cellular factors
that impact WNV neutralization since they can be used to
infect a variety of cell lines and primary cell types including
those that do not support plaque formation. Overall, we found
that RVP-based measurements of antibody-mediated neutrali-
zation could be made accurately and reproducibly while
complying with the assumptions of the law of mass action,
provided that less than 1 ng of E protein antigen was used in
each assay.Antibody-dependent enhancement of WNV RVP infection
Significant experimental evidence supports a role for
antibodies in protection from flavivirus infection and the
establishment of immunity following vaccination (reviewed
in Roehrig et al., 2001). However, under some circum-
stances, antibodies may have pathogenic consequences as
they can enhance infection of FcgR-expressing cells
(reviewed in Halstead, 2003). To evaluate the feasibility of
investigating antibody-dependent enhancement of infection
(ADE) using our assay, WNV RVPs were incubated in the
presence of decreasing concentrations of mAb 7H2 for 1 h,
and then incubated with K562 cells, an erythroleukemic
human cell line that expresses FcgRII (CD32) and has been
Fig. 7. Antibody-mediated enhancement of WNV RVP infection. WNV RVPs
were produced by transfection of BHK WNIIrep-GFP cells with plasmids
encoding a WNV C-prM fusion protein and E protein (using a plasmid ratio of
3:1 by mass). RVPs were harvested at 48 h post-transfection, filtered,
characterized by ELISA, and frozen at 80 -C. RVPs were thawed, diluted
to a concentration of less than 10 ng/ml E protein antigen, and incubated in the
presence of the indicated concentrations of 7H2 in triplicate for 1 h at room
temperature. RVP–antibody complexes were then added to K562 cells in a
total volume of 300 Al. Infection was monitored 36 h later as a function of GFP
expression using flow cytometry. The percent of GFP-expressing cells at each
concentration of antibody is indicated with error bars representing the standard
deviation. The percentage of K562 cells infected in the absence of antibody was
less than 0.5%.
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et al., 2004; Littaua et al., 1990). Under typical infection
conditions, these cells are poorly permissive for WNV
infection (less than 0.5% GFP positive cells in the absence
of antibody). We observed a large (>50-fold) degree of
enhancement of RVP infection in the presence of sub-
neutralizing concentrations of mAb 7H2 (Fig. 7). Similar
results were obtained if infections were performed with
RVPs encapsidating a replicon encoding luciferase and with
a replication competent molecular clone of WNV (Pierson et
al., 2005).
Discussion
Genetically modified virus particles that encode reporter
genes provide a rapid and quantitative method for the study of
virus entry in vitro. In this study, we describe the production
and application of virus-like particles that encapsidate a WNV
replicon for the study of antibody-mediated neutralization of
WNV infection. This approach is well suited for neutralization
studies because RVPs are capable of only a single round of
infection and share many of the structural, biochemical, and
functional properties of fully infectious virus particles (Khro-
mykh et al., 1998; Scholle et al., 2004). Methods for the
production of RVPs were adapted from an elegant series of
studies by Khromykh and colleagues that describe both Kunjin
virus replicons (Varnavski and Khromykh, 1999; Varnavski et
al., 2000) and the complementation of these RNAs with
structural proteins provided in trans by alphavirus vectors
(Jones et al., 2005; Khromykh et al., 1998; Scholle et al., 2004)
or stable packaging cell lines (Harvey et al., 2004). The criteria
used to develop our RVP production approach were to perform
RVP-based measurements of neutralization under conditionsthat satisfy the assumptions of the law of mass action. To
achieve this, three aspects of RVP production were considered.
First, we sought to develop a flexible strategy to study
antibody-mediated neutralization of envelope proteins from a
variety of different WNV isolates. We optimized methods for
the production of WNV RVPs by complementation of a DNA-
launched WNV replicon with standard eukaryotic expression
plasmids that encode the capsid and prM-E proteins of WNV.
A strength of this complementation approach is that it allows
the production of RVPs that incorporate the structural proteins
of WNV using expression vectors that are readily transfected
into cells, in widespread use in the field, and amenable to
straightforward and high-throughput cloning methods such as
site-directed mutagenesis. By comparison, complementation
strategies employing alphavirus vectors (Jones et al., 2005;
Khromykh et al., 1998; Scholle et al., 2004) or stable
packaging cell lines (Gehrke et al., 2003; Harvey et al.,
2004) are less versatile but may be capable of production at
higher titers. Our complementation approach confers a
considerable degree of flexibility by permitting the production
of RVPs that incorporate the structural components of
different virus strains simply by changing the combination
of plasmids transfected into producer cells. To date, we have
produced RVPs incorporating the prM-E proteins of several
different strains and mutants of WNV (Hanna et al., 2005; T.
Pierson, unpublished data), as well as the distantly related
dengue and Langat viruses (Whitby et al., 2005; Davis et al.,
in press).
Second, RVP production approaches were optimized for
the study of antibody-mediated neutralization under condi-
tions that satisfy the assumptions of the law of mass action. In
this regard, minimizing the concentration of non-infectious E
protein antigen present in RVP preparations was essential.
Although infectious RVPs were produced at similar titers after
complementation with plasmids encoding the WNV structural
genes in four different configurations, the ratio of infectious
to non-infectious particles was markedly different. The two
production strategies that utilized a capsid-prM fusion protein
resulted in RVP stocks with a relatively low concentration of
non-infectious E protein. When considered as a function of
the infectious titer, the concentration of antigen present in
stocks of RVPs produced using C-prM-E and C-prM + E
strategies is quite similar to that of stocks of infectious WNV
harvested from mosquito cell cultures three days after
infection (approximately 3800–10,000 PFU of WNV/ng E
protein vs. +1000 infectious RVP/ng E protein; data not
shown). In contrast, RVPs prepared by expression of capsid
and prM-E proteins on two separate plasmids yielded
significantly higher concentration of antigen (>50-fold),
despite an equivalent infectious titer. This in turn decreases
the utility of particles produced using this strategy for
neutralization studies.
We suggest that the discrepancy in the relative proportions
of infectious and non-infectious particles may reflect differ-
ences between the requirements for the release of non-
infectious subviral particles (composed solely of envelope
prM and E proteins) (Konishi et al., 1992), from those directing
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RNA) (Lee et al., 2000). In our system, RVPs were produced
by transfection of three or four different plasmids into cells.
Although a significant percentage of cells will take up all of the
plasmids present in the transfection mixture, a fraction of cells
will receive only a single plasmid. When producing RVPs with
capsid and prM-E expression vectors (C + prM-E) the fraction
of cells transfected with only the prM-E expression plasmid
will have the ability to release large amounts of non-infectious
SVPs into the supernatant. In support of this, reducing the mass
of the prM-E expression plasmid in the transfection mix
relative to the other plasmid components allowed RVP
production associated with significantly reduced concentration
of antigen (data not shown). In contrast, for C-prM + E and C-
prM-E production strategies, a requirement for cleavage at the
C-prM junction coupled with the required role of prM in
folding and trafficking of E protein (Allison et al., 1995)
imposes a requirement for the simultaneous expression of all
four components (replicon, capsid, prM, and E) on secretion of
E protein antigen. Our results provide direct support for the
importance of the viral protease-mediated cleavage event
between capsid and prM in regulating the kinetic and temporal
relationships that balance prM-E mediated formation of a virus
particle and the requirements for incorporation of RNA and
capsid protein (Lobigs and Lee, 2004). While an important
caveat to consider for structure–function studies, the ability to
manipulate the relative proportion of infectious SVPs, and thus
the concentration of E protein antigen, present in RVP
preparations proved to be a critical aspect of the development
of RVP-based methods for investigating antibody-mediated
neutralization.
A third consideration when selecting methods for the
production of WNV RVPs is the potential for the formation
of infectious WNV genome by recombination. While
recombination during trans-encapsidation of flavivirus repli-
cons to yield infectious viral genomes has not yet been
reported, it has been proven to be of significant concern in
related alphavirus replicon systems (Vasilakis et al., 2003 and
references within). The use of DNA plasmids to launch both
replicon and structural gene RNAs confers a significant
degree of flexibility to our approach but may also increase
the potential for recombination during RVP production.
Recombination between DNA plasmids following transfec-
tion is well documented and is a property often exploited for
the production of infectious virus using molecular clone
technology of other viral systems including HIV-1, adenovi-
rus, and vaccinia virus (Skrabal et al., 2003). Recombination
is particularly efficient when significant regions of homology
exist between exogenously added plasmids. Unfortunately,
the overlap between the amino-terminus of WNV capsid and
a required RNA cis element in the replicon (C20) imposes a
requirement for sequence homology between the replicon
and capsid expression vector. Likewise, homology exists
between the carboxy-terminus of E protein and the ER
translocation signal of the remaining polyprotein encoded by
the replicon. To reduce the possibility for reversion to a fully
infectious virus, our production strategies used at least threecomponents imposing a requirement for at least two
independent recombination events for the restoration of a
wild type genome. Since RVPs produced using C-prM-E and
C-prM + E complementation strategies are equivalent with
respect to both infectious titer, concentration of E protein
antigen present, and recognition by neutralizing antibodies
(data not shown), the C-prM + E strategy was used for
neutralization studies.
The standard method for detecting neutralizing antibodies
against WNV is the plaque reduction neutralization test
(PRNT) (Lindsey et al., 1976; Morens et al., 1985; Russell
and Nisalak, 1967; Russell et al., 1967). Using this approach,
the ability of antibody to bind virus and prevent infection is
measured as a reduction in the number of plaques formed
following infection of monolayers of permissive cells. While
the use of this methodology has allowed for great insight into
flavivirus biology and pathogenesis, it has several limitations.
First, the PRNT assay is relatively slow, requiring 3–4 days for
plaque formation and analysis, and is logistically difficult to
perform in large scale. Second, only cell types upon which the
virus readily forms plaques may be used to investigate
neutralization of WNV. Thus, the PRNT approach does not
allow the neutralization capacity of antibodies to be detected
using virus strains that plaque poorly or on permissive cell
types that do not form monolayers. Because cellular factors
may impact the outcome of antibody–virus interactions, a
capacity to measure neutralization in several cellular contexts,
including those that reflect targets of WNV infection in vivo, is
strongly desirable. Third, the quantitative power of the PRNT
is subject to the number of wells examined and number of
plaques counted manually by the investigator. The latter
process is somewhat subjective when plaque size and
morphology is variable. Finally, the PRNT approach involves
the use of live infectious virus, which must be handled by a
skilled investigator in an appropriate biocontainment facility.
The application of RVPs for the study of antibody-
mediated neutralization has several desirable features that
complement the PRNT. Infection of cells by RVPs is
measured directly as a function of reporter gene activity,
allowing the study of virus entry and its inhibition on a
variety of cells types, including those that do not support the
formation of plaques. This is particularly useful when
studying ADE on non-adherent Fc-receptor bearing cell lines.
RVP-based measurements of neutralization studies can be
performed rapidly (2 days) and on large scale using a 96-well
plate format. Analysis of a large number of independent
experiments assayed on different days with different prepara-
tions of RVPs revealed that this approach allows a significant
degree of precision and reproducibility. Significantly, neutral-
ization studies using RVPs allow the analysis of a panel of
different WNV strains or lineages without a requirement to
isolate infectious clones of each virus strain of interest nor
manipulate them in a BSL-3 facility.
A critical and innovative aspect of an RVP approach for
measuring neutralization is the normalization criteria employed
for each experiment. In contrast to the PRNT assay, the amount
of RVPs used in each experiment was determined as a function
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infectious titer. Importantly, no assumptions are made regarding
the nature of the antigen in RVP preparations, reducing the
impact of variations in the particle to infectious particle ratios of
RVP (or virus) preparations. We arrived at these criteria by
determining experimentally that it is not appropriate to assume
the antigen content of virus preparations is sufficiently low to
allow study under conditions of ‘‘antibody excess’’, particularly
when the affinity of the antibody studied is high. This criterion,
however, is not uniquely suited to the use of RVPs. We have also
observed the concentration of antigen present in stocks of
infectious WNV can vary significantly (100-fold) depending
upon the cell line and conditions of production, and that the
infectious to non-infectious particle ratio varies greatly among
different strains of flaviviruses (M. Diamond, E. Harris, and T.
Pierson, unpublished data). The ability of flavivirus infected
cells to shed viral antigen in the form of defective mature virus
particles, or SVPs composed solely of prM-E, introduces
additional challenges for the study of antibody-mediated
neutralization or ADE. For both infectious virus and RVPs
produced by complementation, the use of antigen as a critical
normalization parameter provides a direct method to ensure each
experiment is performed in accordance with the percentage law.
Understanding the biochemical and cellular factors that
determine the fate of a virus particle bound by antibody is an
important aspect of understanding the requirements for an
effective and safe vaccine. For flaviviruses, this is complicated
by an ability of both neutralizing and non-neutralizing
antibodies to facilitate infection under some circumstances
and possibly, as in secondary DEN infection, contribute to
pathogenesis (Halstead, 2003). The application of RVPs to
study the mechanism of neutralization and enhancement allows
a direct and quantitative measurement of antibody–virus
particle interactions in variety of cellular contexts and will
allow novel approaches to determine the mechanisms of
antibody-mediated neutralization and enhancement.
Materials and methods
Cell lines
Human embryonic kidney cells (HEK)-293T, HeLa cells,
Vero, and Baby hamster kidney (BHK-21) clone 15 cells were
maintained in Dulbecco’s modified essential media (DMEM)
(Life Technologies, Gaithersburg, MD) containing 10% fetal
calf serum (FCS), and 1% penicillin/streptomycin (P/S)
(Invitrogen, Carlsbad, CA). BHK-21 cell lines that stably
propagate WNV replicons were maintained in DMEM/10%
FCS/1% P/S supplemented with 10Ag/ml of blasticidin S
(Invitrogen, Carlsbad, CA). K562 cells were grown in RPMI
supplemented with 10% FCS and 1%P/S. All cell lines were
maintained at 37 -C in 5% CO2.
Construction of a sub-genomic WNV replicon
Construction of a panel of DNA-launched sub-genomic
WNV replicons was accomplished by modification of apreviously described infectious molecular clone of a lineage
II strain of WNV (strain: WN 956 D117 3B). The objective
was to build a replicon in a configuration that simplified the
introduction of one or more reporter genes and allowed
expression in eukaryotic cells following transfection of the
plasmid, eliminating a requirement for production and purifi-
cation of RNA in vitro. The starting material for these studies
was plasmid (pSP6WN/Xba) encoding WNV under the
transcriptional control of the SP6 promoter (kindly provided
by Dr. Vladimir Yamshchikov (University of Kansas))(Wengler
and Gross, 1978; Yamshchikov et al., 2001). Replicons were
constructed in several steps employing standard methods of
molecular cloning.
The first step in construction involved the introduction of a
unique NotI restriction endonuclease recognition site into the 3V
UTR, positioned 24 nucleotides downstream of the stop codon
of the WNV ORF. The purpose of this site was to allow the
introduction of reporter genes or drug resistance markers into
the replicon under the translational control of an internal
ribosome entry site (IRES). This was accomplished using an
overlap extension PCR approach to synthesize a DNA
fragment containing the NotI site into the 3V UTR, followed
by insertion back into the parental vector using unique AvrII
and XbaI sites in SP6WN/Xba (to create vector pSP6WNV-
Not). To minimize the potential for recombination during this
and subsequent cloning steps, plasmid propagation was
performed in Stbl2 rec bacteria (Invitrogen, Carlsbad, CA)
grown for 22–24 h at 30 -C in LB broth. Next, a reporter gene
cassette composed of the green fluorescent protein (GFP) and
hygromycin B phosphotransferase (Hph) positioned down-
stream of the EMCV IRES was cloned into the NotI site (to
generate vector pSP6WNV-IHF).
A second major modification involved replacement of the
majority of sequence encoding the viral structural proteins
with the 2A autoprotease of foot and mouth disease virus
(FMDV) and a second unique MluI restriction site. This step
was accomplished using overlap extension PCR method in
which the novel MluI site and the 19 amino acids of the
FMDV 2a protease was engineered into the overlapping
primer set. The resulting PCR fragment was cloned into
unique ClaI and NsiI sites in pSP6WNV-IHF (to create the
replicon vector pWrep2a-IHF).
To eliminate a requirement for the synthesis and purification
of replicon RNA in vitro, two further modifications of
pWrep2a-IHF were made. First, a ribozyme from the hepatitis
delta virus (HDV) and a SV40 polyadenylation signal were
cloned adjacent to the 3V terminus of the WNV cDNA (Fodor et
al., 1999) such that ribozyme-mediated cleavage of the replicon
RNA occurs to define the end of the RNA as the terminal
nucleotides of the WNV genome. A fragment containing these
two components was assembled using overlap extension PCR
and cloned into a unique XbaI site (blunted with mung bean
nuclease) of pWrep2a-IHF. Next, a CMV promoter/enhancer
was engineered upstream of the first nucleotide of the WNV
genome using an overlap extension PCR strategy and unique
ClaI and NsiI sites in pWrep2aH-IHF, creating a ‘‘DNA-
launched’’ replicon (pWIIrep-IHF). Care was taken to ensure
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to initiate at the 5V terminal nucleotide of the WNV genome.
Correct placement of both the CMV promoter and HDV
ribozyme were required to ensure that the RNA pol II messages
produced following plasmid transfection would result in the
production of WNV RNAs with the authentic terminal residues
required for RNA replication.
Subsequently, a large number of additional replicons were
constructed by simply substituting different gene cassettes into
the unique MluI and NotI sites present at the 5V and 3V ends of
the replicon (no reporter genes: WNIIrep, GFP: WNIIrep-GFP,
Firefly luciferase: WIIrep-fLUC, Renilla luciferase: WNIIrep-
REN, GFP + blasticidin resistance: WNIIrep-GFP-IB, Renilla
luciferase + blastiticidin resistance: WNIIrep-REN-IB). Repli-
cons were characterized by transfection of HEK-293T cells
with 4Ag of plasmid using Lipofectamine 2000 (according to
the manufacturer’s protocol) and quantifying reporter gene
expression 48 h later. In addition, replicon RNAs were
evaluated for their ability to replicate and be packaged into
pseudo-infectious reporter virus particles as described below.
WNV structural protein expression vectors
The structural genes of WNV were cloned into several
different expression vectors for use in the production of RVPs.
A plasmid encoding the prM-E genes of the NY99 strain of
WNV (pCBWN) was provided by Dr. Gwong Jen J. Chang
(CDC)(Davis et al., 2001). pCBWN is a pcDNA3-based
plasmid encoding a modified form of the WNV prM-E protein
in which the signal sequence of WNV prM has been replaced
with that of Japanese encephalitis virus in order to improve
expression. The prM and E genes were amplified individually
and as a prM-E fusion protein from this vector using PCR and
cloned into the Gateway entry vector pENTR/D-TOPO
(Invitrogen) using topoisomerase I-mediated cloning methods.
Subsequently, these genes were transferred by Gateway LR
recombination into pcDNA6.2/V5-DEST (Invitrogen) to gen-
erate WNI prM 6.2, WNI E 6.2, and WNI prM-E 6.2.
Plasmids encoding capsid-prM (C-prM) or capsid-prM-E (C-
prM-E) fusion proteins created by cloning PCR fragments into
unique NheI and BamHI sites of pIRESHygro2 (Clonetech).
WNV capsid was cloned from SP6WN/Xba into the Gateway
system and subsequently into pcDNA 6.2 as described above
(WNII Cap).
Production of pseudo-infectious WNV reporter virus particles
(RVPs)
WNV RVPs were produced in HEK-293T cells by trans-
fection with an equal mass (1.3 Ag) of three DNA plasmids
encoding: a replicon, capsid, and prM-E using Lipofectamine
2000 according to the manufacturer’s instruction (Invitrogen).
Lipid–DNA complexes were washed off transfected cells 4–
12 h post-infection and replaced with a low glucose
formulation of DMEM. The rational for using low glucose
media is a significantly reduced rate of acidification of the
media, which can inactivate pH-sensitive flavivirus particles.RVP-containing supernatants were harvested 48 h post-trans-
fection, filtered, and used to infect target cells or frozen as
described below.
A second method for RVP production involved transfection
of a BHK cell line that stably propagates a bicistronic WNV
replicon under antibiotic selection (10 Ag/ml blasticidin).
Preparation of RVPs using this system was accomplished by
transfection of pre-plated cells with plasmids encoding capsid
and prM-E. RVPs were produced by transfection of this
replicon stable cell line with WNV structural protein expres-
sion vectors in several configurations and with varying ratios of
DNA plasmids. Optimized RVP production conditions were
determined and involved transfection of replicon stable cells in
a T75 flask with 30 Ag of C-prM vector and 10 Ag of WNV E
expression plasmid.
Cryo-preservation of RVPs was performed using two
methods. Our initial studies were performed by mixing RVPs
with an equal volume of heat-inactivated FCS containing 25
mM HEPES buffer, pH 8.0, followed by storage at 80 -C. In
subsequent studies, we found that the addition of serum was
not as important for virus stability as the presence of HEPES
buffer. Therefore, RVP production conditions were modified
slightly by producing virus particles into a commercially
available low glucose formulation of media that already
contains 25 mM HEPES (Invitrogen). RVP containing super-
natants were then frozen directly. The stability of RVPs stored
using this approach was evaluated and confirmed by period-
ically (n = 6) measuring infectious titer over the course of 2
months. We found that infectivity did not vary significantly
over this period of time.
Infection of target cells with RVPs
Conditions for the infection of target cells were selected to
maximize the linear portion of the curve defining the
relationship between virus/RVP input and the number of
infected cells. Target cells for WNV RVP infection were plated
for infection experiments to achieve approximately 25–50%
confluence at the time of infection. While infection of cells at
higher density was possible, we found the relationship between
virus input and infection saturated at lower levels of infection.
Infections were harvested at 36–48 h post-infection, depending
on the kinetics and quantity of reporter gene expression in the
cell type studied.
Antigen capture ELISA for WNV E protein
To quantify the amount of E protein antigen in virus and
reporter virus preparations, an antigen capture ELISA was
developed based on methodologies developed in our laboratory
for the characterization of WNV monoclonal antibodies
(Sanchez et al., 2005). ELISA plates were prepared by coating
96-well plates for 8–12 h at 4 -C with the E-specific group
reactive mAb 4G2 (100 ng per well) in a buffer composed of
15 mM sodium carbonate and 35 mM sodium bicarbonate in
PBS (pH 9.6). 4G2 coated plates were washed three times prior
to the addition of WNVantigens (wash buffer: 1X PBS, 0.05%
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(PBS), 0.05% Tween-20, 1% bovine serum albumin (BSA)
(blocking buffer). Prior to analysis, E protein-containing
supernatants were lysed in blocking buffer containing 1%
Triton X-100 for at least 5 min, followed by serial two-fold
dilutions in blocking buffer containing 0.1% Triton X-100. The
standard used in this assay was a purified soluble form of the E
protein (NY1999 strain) produced in HEK-293T cells using a
recombinant vaccinia virus expression system as described in
detail (Sanchez et al., 2005). These standards, initially at 125
ng/ml, were lysed and diluted as described above. Each sample
was incubated in 4G2-coated wells for 2 h with gentle shaking
to promote antigen capture, followed by six washes. Wells
were then incubated with 2 Ag/ml of a biotin conjugate of the E
protein-specific monoclonal antibody E1 (Oliphant et al., 2005)
for 1 h, followed by six washes. A horseradish peroxidase
conjugate of streptavidin (400 ng/ml) was used to detect bound
E1 (1-h incubation) and was developed using TMB peroxidase
substrate (KPL, Inc., Gaithersburg, MD). The reaction was
stopped with 2N H2SO4 and read on a MRX Revelation plate
reader at a wavelength of 450 nm.
Neutralization of WNV reporter virus particles
RVPs were produced as described above and frozen. The
concentration of E protein present in each RVP preparation was
measured using an antigen-capture ELISA and diluted in media
to a concentration of less than 10 ng/ml. One hundred
microliters of RVPs was incubated with an equal volume of
media containing monoclonal antibody at varying concentra-
tions at room temperature for 1 h. Targets for RVP infection
were prepared by plating 6–8  103 cells per well of a 96-well
plate 5–6 h prior to infection. Cells were infected in
quadruplicate by replacing the media of the target cells with
RVP–antibody complexes and returned to the incubator for 40
h. For experiments with RVPs encapsidating a replicon
encoding GFP, target cells were harvested by trypsinization,
fixed in 2% paraformaldehyde in PBS, and analyzed by flow
cytometry. For experiments with RVPs encapsidating a
replicon encoding luciferase, infected cells were lysed in 100
Al of commercial lysis reagent (Promega) and assayed using
luciferin-containing substrate as described. Luminescence was
measured using a Wallac luminometer. Data obtained from
neutralization assays were analyzed using non-linear regression
analysis (GraphPad Prism 4, GraphPad Software, Inc). Raw
data were fit to a sigmoidal dose-response (one site competi-
tion) curve constrained with the value of non-infected cells.
The EC50 of an antibody was determined for curves with an R2
value of greater than 0.8.
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